Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer. Their strategy involves leveraging a unique product development platform to efficiently advance their pipeline. Key drug candidates include Envafolimab (a PD-L1 single-domain antibody administered by subcutaneous injection), YH001 (a CTLA-4 antibody with enhanced ADCC and CDC activities), TRC102 (a small molecule inhibitor of DNA base excision repair), and TRC253 (a novel androgen receptor inhibitor). TRACON aims to develop these candidates for various cancer indications, often through collaborations and partnerships.
The San Diego headquarters serves as the central hub for TRACON's operations, including executive management, clinical development oversight, research strategy, business development, finance, and administrative functions.
Located in the University Towne Centre (UTC) area, known for its concentration of life science companies and proximity to research institutions like UC San Diego. The office is likely a modern, professional space designed to facilitate collaboration and innovation.
As a clinical-stage biopharmaceutical company, the work culture is likely fast-paced, science-driven, and results-oriented, with a strong emphasis on teamwork, innovation in oncology, and achieving clinical milestones.
The headquarters' location in San Diego provides TRACON with access to a rich ecosystem of talent, research collaborators, and service providers crucial for a biopharmaceutical company's growth and drug development efforts.
TRACON Pharmaceuticals's global presence is primarily characterized by its clinical trial operations and strategic partnerships. While headquartered in the U.S., the company conducts clinical trials for its oncology drug candidates in multiple countries across North America, Europe, and Asia-Pacific. This involves collaboration with international Contract Research Organizations (CROs), clinical investigators, and research institutions. Their out-licensing and co-development agreements, such as those for Envafolimab, also extend their product development reach into international markets, notably in Greater China.
4350 La Jolla Village Drive, Suite 800
San Diego
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, TRACON Pharmaceuticals' leadership includes:
TRACON Pharmaceuticals has been backed by several prominent investors over the years, including:
Based on publicly available information and recent company announcements, TRACON Pharmaceuticals has maintained stability within its core executive leadership team over the past 12 months, with no major C-suite hires or departures publicly highlighted. The key roles of CEO, CMO, and Principal Financial Officer appear consistently filled.
Discover the tools TRACON Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
TRACON Pharmaceuticals likely utilizes a common corporate email format. While not publicly confirmed, a typical structure for companies of this nature is [first_initial][last]@[companydomain].com.
[first_initial][last]@traconpharma.com
Format
ctheuer@traconpharma.com
Example
80%
Success rate
GlobeNewswire • March 12, 2024
TRACON Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2023. The company also provided updates on its clinical pipeline, including Envafolimab, and key corporate activities....more
GlobeNewswire • January 23, 2024
TRACON Pharmaceuticals announced the pricing of an underwritten public offering of 22,857,143 shares of its common stock and accompanying warrants to purchase up to 22,857,143 shares of common stock. The gross proceeds are expected to be approximately $8.0 million, intended for working capital and general corporate purposes....more
GlobeNewswire • January 9, 2024
TRACON Pharmaceuticals announced that the Biologics License Application (BLA) for envafolimab for adult patients with previously treated microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors has been accepted by China's National Medical Products Administration (NMPA)....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including TRACON Pharmaceuticals, are just a search away.